Nivestim®
ACTIVE PRINCIPLE:
Filgastrim
INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation
DATE:
19/10/2010
STATUS:
Authorized
ACTIVE PRINCIPLE:
Filgastrim
INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation
DATE:
19/10/2010
STATUS:
Authorized